Papers 11–20 of
94
by ScitoVation authors
- L Hedges, S Brown, AK MacLeod, M Moreau, M Yoon, MR Creek, TG Osimitz, and BG Lake. Metabolism of bifenthrin, β-cyfluthrin, λ-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes. Xenobiotica 50 (12) : 1434-1442 (Dec 22, 2020). [abstract] [pubmed]
- A Mistry, LE Bowen, MW Dzierlenga, JK Hartman, and SD Slattery. Development of an in vitro approach to point-of-contact inhalation toxicity testing of volatile compounds, using organotypic culture and air-liquid interface exposure. Toxicol In Vitro 69 : 104968 (Dec 15, 2020). [abstract] [pubmed]
- LG Higgins, LR Chatham, SL Tomczynski, AK MacLeod, M Moreau, HJ Clewell, M Yoon, MR Creek, TG Osimitz, and BG Lake. Differential lymphatic versus portal vein uptake of the synthetic pyrethroids deltamethrin and cis-permethrin in rats. Toxicology 443 : 152563 (Oct 14, 2020). [abstract] [pubmed]
- RA Clewell, JA Leonard, CI Nicolas, JL Campbell, M Yoon, AY Efremenko, PD McMullen, ME Andersen, HJ Clewell, KA Phillips, and YM Tan. Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates. Toxicol In Vitro 66 : 104855 (Aug 8, 2020). [abstract] [pubmed]
- YM Tan, M Chan, A Chukwudebe, J Domoradzki, J Fisher, CE Hack, P Hinderliter, K Hirasawa, J Leonard, A Lumen, A Paini, H Qian, P Ruiz, J Wambaugh, F Zhang, and M Embry. PBPK model reporting template for chemical risk assessment applications. Regul Toxicol Pharmacol 115 : 104691 (Aug 2, 2020). [abstract] [pubmed]
- P Mallick, G Song, AY Efremenko, SN Pendse, MR Creek, TG Osimitz, RN Hines, P Hinderliter, HJ Clewell, BG Lake, M Yoon, and M Moreau. Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids. Toxicol Sci 176 (2) : 460-469 (Aug 1, 2020). [abstract] [pubmed]
- PD McMullen, S Bhattacharya, CG Woods, SN Pendse, MT McBride, VY Soldatow, C Deisenroth, EL LeCluyse, RA Clewell, and ME Andersen. Identifying qualitative differences in PPARα signaling networks in human and rat hepatocytes and their significance for next generation chemical risk assessment methods. Toxicol In Vitro 64 : 104463 (Apr 15, 2020). [abstract] [pubmed]
- MW Dzierlenga, M Moreau, G Song, P Mallick, PL Ward, JL Campbell, C Housand, M Yoon, BC Allen, HJ Clewell, and MP Longnecker. Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. Environ Res 182 : 109017 (Mar 9, 2020). [abstract] [pubmed]
- P Xue, Y Hou, Z Zuo, Z Wang, S Ren, J Dong, J Fu, H Wang, ME Andersen, Q Zhang, Y Xu, and J Pi. Long isoforms of NRF1 negatively regulate adipogenesis via suppression of PPARγ expression. Redox Biol 30 : 101414 (Feb 28, 2020). [abstract] [pubmed]
- L Li, J Fu, D Liu, J Sun, Y Hou, C Chen, J Shao, L Wang, X Wang, R Zhao, H Wang, ME Andersen, Q Zhang, Y Xu, and J Pi. Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression. Redox Biol 30 : 101412 (Feb 23, 2020). [abstract] [pubmed]